STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: The Swedish biotech company Karo Bio (Reuters: KARO.ST) (STO:KARO) today announced that results from a clinical phase II study of the company’s thyroid hormone analog eprotirome, and its additive effects on dyslipidemia in ezetimibe-treated patients, are subject to a scientific presentation.
